6533b832fe1ef96bd129a522
RESEARCH PRODUCT
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives
Carlo MessinaEmmanuela MussoAlessandra CasarinLorena IncorvaiaIda De LucaGiuseppe Badalamentisubject
Oncologymedicine.medical_specialtyImmune-checkpoint inhibitormedicine.medical_treatmentAntineoplastic AgentsPembrolizumab030218 nuclear medicine & medical imagingTargeted therapyTargeted therapyAntineoplastic Agent03 medical and health scienceschemistry.chemical_compoundImmunologic Factor0302 clinical medicineInternal medicinemedicineHumansImmunologic FactorsRadiology Nuclear Medicine and imagingEribulinMolecular Targeted TherapyPrecision MedicineOlaratumabSoft tissue sarcomabusiness.industrySoft tissueSarcomaGeneral Medicinemedicine.diseasePrecision medicineClinical Practicechemistry030220 oncology & carcinogenesisSarcomabusinessPembrolizumabHumanForecastingEribulinOlaratumabmedicine.drugdescription
Soft tissue sarcomas (STSs) represent a rare and heterogeneous group of solid tumours derived from mesenchymal progenitors and account for 1% of all adult malignancies. Although in the last decade anthracycline-based chemotherapy single agent or in combinations has been able to improve clinical benefits, prognosis is still poor and STSs represent an important unmet medical need. Continuous advances in cancer genetics and genomics have contributed to change management paradigms of STSs as it occurred for other solid tumours. Several treatments have been recently developed with the specific aim of targeting different cell pathways and immune-checkpoints that have been recognized to drive tumour progression. The following attempts to provide a review of literature focusing on the available data concerning novel treatments and future prospective for the management of metastatic STSs.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-02-20 | La radiologia medica |